| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology, Pathobiology and Genetics |
Department of Pathology and The Cancer Center, University of Illinois at Chicago, Chicago, Illinois
Requests for reprints: Vitalyi Senyuk, Department of Pathology, University of Illinois at Chicago, Molecular Biology Research Building, Room 3312, M/C 737, 900 South Ashland Avenue, Chicago, IL 60607. Phone: 312-413-2875; E-mail: vsenyuk{at}uic.edu.
AML1/MDS1/EVI1 (AME) is a chimeric transcription factor produced by the (3;21)(q26;q22) translocation. This chromosomal translocation is associated with de novo and therapy-related acute myeloid leukemia and with the blast crisis of chronic myelogenous leukemia. AME is obtained by in-frame fusion of the AML1 and MDS1/EVI1 (ME) genes. The mechanisms by which AME induces a neoplastic transformation in bone marrow cells are unknown. AME interacts with the corepressors CtBP and HDAC1, and it was shown that AME is a repressor in contrast to the parent transcription factors AML1 and ME, which are transcription activators. Studies with murine bone marrow progenitors indicated that the introduction of a point mutation that destroys the CtBP-binding consensus impairs but does not abolish the disruption of cell differentiation and replication associated with AME expression, suggesting that additional events are required. Several chimeric proteins, such as AML1/ETO, BCR/ABL, and PML/RARa, are characterized by the presence of a self-interaction domain critical for transformation. We report that AME is also able to oligomerize and displays a complex pattern of self-interaction that involves at least three oligomerization regions, one of which is the distal zinc finger domain. Although the deletion of this short domain does not preclude the self-interaction of AME, it significantly reduces the differentiation defects caused in vitro by AME in primary murine bone marrow progenitors. The addition of a point mutation that inhibits CtBP binding completely abrogates the effects of AME on differentiation, suggesting that AME induces hematopoietic differentiation defects through at least two separate but cooperating pathways.
This article has been cited by other articles:
![]() |
V. Senyuk, K. K. Sinha, D. Li, C. R. Rinaldi, S. Yanamandra, and G. Nucifora Repression of RUNX1 Activity by EVI1: A New Role of EVI1 in Leukemogenesis Cancer Res., June 15, 2007; 67(12): 5658 - 5666. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Li, K. K. Sinha, M. A. Hay, C. R. Rinaldi, Y. Saunthararajah, and G. Nucifora RUNX1-RUNX1 Homodimerization Modulates RUNX1 Activity and Function J. Biol. Chem., May 4, 2007; 282(18): 13542 - 13551. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. B. Dammer, A. Leon, and M. B. Sewer Coregulator Exchange and Sphingosine-Sensitive Cooperativity of Steroidogenic Factor-1, General Control Nonderepressed 5, p54, and p160 Coactivators Regulate Cyclic Adenosine 3',5'-Monophosphate-Dependent Cytochrome P450c17 Transcription Rate Mol. Endocrinol., February 1, 2007; 21(2): 415 - 438. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Laricchia-Robbio, R. Fazzina, D. Li, C. R. Rinaldi, K. K. Sinha, S. Chakraborty, and G. Nucifora Point Mutations in Two EVI1 Zn Fingers Abolish EVI1-GATA1 Interaction and Allow Erythroid Differentiation of Murine Bone Marrow Cells Mol. Cell. Biol., October 15, 2006; 26(20): 7658 - 7666. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |